BUSINESS SEGMENT INFORMATION (Tables)

9 Months Ended

Sep. 30, 2012

Segment Reporting [Abstract]

Net sales of key products [Text Block]

		Three Months Ended September 30,				Nine Months Ended September 30,
Dollars in Millions		2012		2011		2012		2011
Plavix* (clopidogrel bisulfate)		$	64	$	1,788	$	2,498	$	5,415
Avapro*/Avalide* (irbesartan/irbesartan-hydrochlorothiazide)			95		216		419		757
Eliquis (apixaban)			-		-		1		-
Abilify* (aripiprazole)			676		691		2,008		2,021
Reyataz (atazanavir sulfate)			363		391		1,127		1,153
Sustiva (efavirenz) Franchise			370		359		1,144		1,073
Baraclude (entecavir)			346		311		1,028		878
Erbitux* (cetuximab)			173		172		531		510
Sprycel (dasatinib)			263		211		738		576
Yervoy (ipilimumab)			179		121		495		216
Orencia (abatacept)			307		233		851		660
Nulojix (belatacept)			3		-		7		2
Onglyza/Kombiglyze (saxagliptin/saxagliptin and metformin)			178		127		511		320
Byetta* (exenatide)			55		-		55		-
Bydureon* (exenatide extended-release for injectable suspension)			20		-		20		-
Mature Products and All Other			644		725		1,997		2,209
	Net Sales	$	3,736	$	5,345	$	13,430	$	15,790